Senti Biosciences Holdings Inc (SNTI)

Senti Biosciences, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker SNTI. The company focuses on cell and gene therapy programs built around its gene circuit platform, with an emphasis on engineered cell therapies for serious diseases. Its pipeline includes SENTI-202, an off-the-shelf CAR-NK therapy being developed for blood cancers and relapsed or refractory hematologic malignancies, including acute myeloid leukemia, and SENTI-301A, an off-the-shelf CAR-NK therapy under development for solid tumors and hepatocellular carcinoma. Senti Biosciences also works on a paired antigen discovery platform used to identify and validate tumor-related targets, alongside additional preclinical and partnered programs in gene therapy, cell therapy, and regenerative medicine. The company was incorporated in 2016 and is based in South San Francisco, California.

Jump directly to the stock analysis sections supported by the latest available data.